FXYD5 and cancer: Intriguingly, we presented additional evidence that dysadherin was involved in ECM remodeling, as indicated by the data of GSEA (Figure S14), suggesting potential involvement of dysadherin in the dynamics of ECM remodeling, which occurs during cancer progression 15, 64.